Top View
- Pharmacology Review(S)
- Imatinib Resistance and Microcytic Erythrocytosis in a Kit Gatekeeper-Mutant Mouse Model of Gastrointestinal Stromal Tumor
- Nexavar, INN-Sorafenib
- Trastuzumab Emtansine Is Active on HER-2 Overexpressing NSCLC Cell
- Molecular Targeting of HER2-Overexpressing Biliary Tract Cancer Cells with Trastuzumab Emtansine, an Antibody–Cytotoxic Drug Conjugate
- Evaluation of the KIT/Stem Cell Factor Axis in Renal Tumours
- Qtc Interval Prolongation with Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors
- Metformin Reverses Stem Cell‑Like Hepg2 Sphere Formation and Resistance to Sorafenib by Attenuating Epithelial‑Mesenchymal Transformation
- New Knowledge of the Mechanisms of Sorafenib Resistance in Liver Cancer
- Sorafenib and Sunitinib in Renal Cell Carcinoma Mark N
- NEXAVAR (Sorafenib) Tablets, for Oral Use QT Prolongation: Monitor Electrocardiograms and Electrolytes in Initial U.S
- Adult Antiemetic Management of Chemotherapy-Induced Nausea
- Assessment of Vitamin D Levels in Newly Diagnosed Breast Cancer
- Lenvatinib (Lenvima™), Pazopanib (Votrient®), Sorafenib (Nexavar®) EOCCO POLICY Policy Type: PA/SP Pharmacy Coverage Policy: EOCCO166
- Pazopanib in Renal Cell Carcinoma
- Efficacy and Safety of Sorafenib Versus Sunitinib As First-Line Treatment in Patients with Metastatic Renal Cell Carcinoma
- Sorafenib Inhibits Imatinib-Resistant KIT and Platelet-Derived Growth
- Highlights from ASCO-GI 2021 from EORTC Gastrointestinal Tract Cancer Group ✉ Thibaud Koessler 1,2,3 , Maria Alsina3,4, Dirk Arnold3,5, Irit Ben-Aharon3,6, Manfred P
- Durable Response with a Combination of Imatinib and Sorafenib in KIT Exon 17 Mutant Gastrointestinal Stromal Tumor
- Limited Clinical Activity of Nilotinib and Sorafenib in FIP1L1-PDGFRA Positive Chronic Eosinophilic Leukemia with Imatinib-Resistant T674I Mutation
- Tyrosine Kinase Inhibitor Treatments in Patients with Metastatic Thyroid Carcinomas: a Retrospective Study of the TUTHYREF Network
- Oncology Progress Against Cancer
- 919 1. Abstract 2. Introduction Kit
- Rare Complications of Multikinase Inhibitor Treatment
- Oral Targeted Therapy for Cancer
- Receptor Tyrosine Kinase Inhibitors for Treatment of Pediatric Solid Tumors
- Clinical Trials Appendix Q1 2019 Results Update
- Clinical Trials Appendix Q1 2021 Results Update
- Sorafenib in Patients with Hepatocellular Carcinoma – Results of the Observational
- Synergistic Inhibition of HCC and Liver Cancer Stem Cell Proliferation by Targeting RAS/RAF/MAPK and WNT/Β-Catenin Pathways
- Drug-Related Pneumonitis in Cancer Treatment During the COVID-19 Era
- Vandetanib (Caprelsa®) Abbreviated National Drug Monograph May 2015 VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives
- Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable Or Metastatic Breast Cancer After Two Or More Anti- HER2 Therapies Confidential Until Published
- Nanotechnology of Tyrosine Kinase Inhibitors in Cancer Therapy: a Perspective
- Theranostics Targeted Sequencing Reveals the Mutational Landscape Responsible for Sorafenib Therapy in Advanced Hepatocellular C
- Effects of Combined Admistration of Imatinib and Sorafenib in a Murine
- Dual Targeting of Sorafenib-Resistant HCC-Derived Cancer Stem Cells
- Inhibition of FLT3 in AML: a Focus on Sorafenib
- Tyrosine Kinase Inhibitor-Induced Macrocytosis
- Induction of Endoplasmic Reticulum Stress by Sorafenib and Activation of NF-Kb by Lestaurtinib As a Novel Resistance Mechanism in Hodgkin Lymphoma Cell Lines
- Publication Agenda CHMP 07-10 December 2020
- The TGF-Β Pathway: a Pharmacological Target in Hepatocellular Carcinoma?
- Pharmacological Research the Role of Small Molecule Kit Protein-Tyrosine
- T Cell Reduction Correlates with Survival of HCC Patients After Sorafenib Therapy
- Thyroid Effects of Tyrosine Kinase Inhibitors
- Sorafenib and Nilotinib Resensitize Tamoxifen Resistant Breast Cancer Cells to Tamoxifen Treatment Via Estrogen Receptor Α
- FLT3 Inhibitors for the Treatment of Acute Myeloid Leukemia
- Overcoming Resistance to FLT3 Inhibitors in the Treatment of FLT3-Mutated AML